Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Denintuzumab Mafodotin

Known as: DENITUZUMAB MAFODOTIN, Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody 
An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BACKGROUND Denintuzumab mafodotin (SGN-CD19A) is a CD19-targeting antibody-drug conjugate, comprising a monoclonal antibody… Expand
Is this relevant?
Review
2019
Review
2019
BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent… Expand
Is this relevant?
2019
2019
Abstract Background In BMA117159, GSK2857916, a humanised (IgG1), afucosylated, anti-BCMA monoclonal antibody conjugated to… Expand
Is this relevant?
2016
2016
Denintuzumab Mafodotin (SGN-CD19A) is an antibody-drug conjugate (ADC) composed of an anti-CD19 antibody attached to a synthetic… Expand
Is this relevant?
1987
1987
Human monocytes actively replicate dengue virus. To dissect the primary immune responses to dengue virus-infected monocytes (DV… Expand
  • table I
  • table II
  • table III
  • table IV
  • figure 1
Is this relevant?
1987
1987
Patients with myeloma have a depressed capacity to respond to antigenic challenge. Studies in this laboratory have previously… Expand
Is this relevant?
1986
1986
A limiting dilution procedure using lymphocytes isolated by FACS is described to assess the role of individual T cell subsets for… Expand
Is this relevant?